Skip to main content
OpenTrials
Completed

NCT Number: NCT03492385

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and without ticagrelor pretreatment when administered to healthy male and female subjects.

Up to 6 dose levels will be evaluated. This study will have up to 10 cohorts and up to a total of approximately 76 subjects with either 4 or 8 healthy young subjects in Cohorts 1 through 9 or approximately 16 older subjects in Cohort 10. The starting dose of PB2452 will be 100 mg and the planned doses for subsequent cohorts are 300, 1000, 3000, 9000, and 18000 mg.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

PPD

Austin, Texas, 78744, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is male or female between 18 and 50 years of age, inclusive.
  • The subject has a body mass index between 18 and 35 kg/m2 and a weight of ≥50 kg but ≤120 kg, inclusive, at screening.
  • The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12 lead ECG results, and physical examination findings at screening.

Specific inclusionary laboratory values at screening and check-in require the following:

  • Aspartate transaminase (AST), alanine transaminase (ALT), total serum bilirubin and alkaline phosphatase levels within the normal range as defined by the clinical laboratory
  • White blood cell (WBC) count, platelet count and hemoglobin level within the normal range as defined by the clinical laboratory
  • Thyroid stimulating hormone (TSH) level within the normal range as defined by the clinical laboratory at screening
  • Prothrombin time (PT) and partial thromboplastin time (PTT) level within the normal range as defined by the clinical laboratory
  • Female subjects of childbearing potential must not be pregnant, lactating, or planning to become pregnant before 3 months after the last dose of study drug, and have a negative serum pregnancy test at screening and check-in. Female subjects of childbearing potential must use 2 effective methods of birth control (ie, oral, implantable, patch, or injectable contraceptives in combination with a condom, hormone-containing intrauterine device that has been in place for at least 2 months prior to screening in combination with a condom, double-barrier method [ie, condoms, sponge, diaphragm, or cervical cap with spermicidal gels or cream], or vasectomy for male subjects or male partners of female subjects) from 30 days before study drug administration through the end of the study. Women are considered not to be of childbearing potential if they have fulfilled one of the following criteria: documentation of irreversible surgical sterilization (ie, hysterectomy, or bilateral oophorectomy [not tubal ligation]), or postmenopausal (defined as amenorrhea for 12 consecutive months following cessation of all exogenous hormonal treatments, and documented plasma follicle-stimulating hormone level >40 IU/mL or amenorrhea for 24 consecutive months). Male subjects with partners of childbearing potential must agree to use appropriate and effective measures of contraception (eg, condom plus diaphragm with spermicide; condom plus spermicide) during the study and for 30 days after the last dose of study drug, and to refrain from donating sperm for at least 7 days prior to the first dose of study drug until at least 90 days following the last dose of study drug.
  • The subject agrees to comply with all protocol requirements.
  • The subject is able to provide written informed consent.

Exclusion criteria

  • History of any clinically significant acute or chronic disease or medical disorder.
  • History or presence of gastrointestinal, hepatic (with the exception of Gilbert's syndrome), or renal disease or renal insufficiency (ie, estimated glomerular filtration rate <60 ml/min/1.73m2), or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study drug or any planned surgical procedure that will occur during the study (from screening through the Day 28 follow up visit).
  • Any clinically significant abnormal findings in physical examination, vital signs, laboratory assessments, and ECG parameters identified during screening or check-in.
  • Any history of arterial or venous thrombosis, including any of the following:
  • History of transient ischemic attack, cardiovascular accident, stroke (ischemic or hemorrhagic), unstable angina, myocardial infarction, or peripheral arterial disease
  • History of deep venous thrombosis, pulmonary embolus, thrombophlebitis, or cavernous malformations
  • Any increased risk of bleeding, including the following:
  • Recent history (within 30 days preceding the first dose of study drug) of gastrointestinal bleeding
  • Any history of severe head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy
  • Any history of intracranial, intraocular, retroperitoneal, or spinal bleeding
  • Any recent (within 30 days preceding the first dose of study drug) major trauma
  • History of hemorrhagic disorders that may increase the risk of bleeding (eg, hemophilia, von Willebrand's disease)
  • Receiving chronic treatment with nonsteroidal anti-inflammatory drugs (including aspirin [greater than 100 mg daily]), anticoagulants, or other antiplatelet agents that cannot be discontinued (including clopidogrel, prasugrel, ticlopidine, dipyridamole, or cilostazol).
  • Have taken, within 30 days of screening, any oral or parenteral anticoagulant, including low molecular-weight heparin
  • Have taken non-steroidal anti-inflammatory medications, including aspirin, within 14 days of screening
  • The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening.
  • Any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of the study data or are considered unlikely to comply with study procedures, restrictions, and requirements as judged by the investigator.
  • Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers, which cannot be stopped within at least 5 half-lives, but not shorter than 10 days, before randomization (a list of examples can be found in Section 6.2).
  • Any prescription (excluding hormonal birth control) or over the counter medications (except paracetamol [up to 2 g per day]), including herbal or nutritional supplements, within 14 days before the first dose of study drug.
  • The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange containing products (eg, marmalade), or alcohol-, or xanthine containing products within 48 hours before dosing with study drug.
  • The subject is participating in any other study or is taking part in a non medication study which, in the opinion of the investigator, would interfere with the outcome of the study.
  • The subject has received another new chemical entity (defined as a compound which has not been approved for marketing) or any marketed or investigational biologic agent within 30 days of the first administration of study drug in this study. The period of exclusion begins 30 days after the final dose or 5 half-lives of the experimental medication has elapsed, whichever is longer.
  • The subject has involvement with any PhaseBio or study site employee or their close relatives (eg, spouse, parents, siblings, or children whether biological or legally adopted).
  • The subject has previously received MEDI2452 (PB2452).
  • The subject is a smoker or has used nicotine or nicotine containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 3 months before the first dose of study drug.
  • The subject has a known or suspected history of drug abuse (including alcohol) or has a positive test result for drugs of abuse, alcohol, or cotinine (nicotine level above 300 ng/mL) at screening or check-in.
  • The subject has been involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and while confined in the clinical site.
  • The subject has donated blood or plasma within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to the first dose of study drug.
  • The subject has a history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to ticagrelor, any biologic therapeutic agent, or any significant food allergy that could preclude a standard diet in the clinical site.
  • Concern for the inability of the subject to comply with study procedures and/or follow up, or, in the opinion of the investigator, the subject is not suitable for entry into the study.

Treatment and study plan

PB2452 Infusion

Drug

30 minute - 12 hour infusion

Placebo - Sodium Chloride

Drug

30 minute - 12 hour infusion

Ticagrelor Oral Tablet - Pre-Treatment

Drug

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment

Drug

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Day -3 (Cohorts 4 through 10) or Day -1 (Cohorts 1 through 3) until Day 28

    An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related.

  2. Number of Participants With Clinically Significant Laboratory Abnormalities

    Time frame: 30 Day - Starting day of dosing

    Number of participants with clinically significant abnormal laboratory findings for hematology, coagulation, serum chemistry, urinalysis and drug tests.

  3. Change in Diastolic Blood Pressure

    Time frame: Days 1, 2, 3, 4, 7 and 28

    Diastolic blood pressure measurements were measured at specific time points.

  4. Change in Systolic Blood Pressure

    Time frame: Days 1, 2, 3, 4, 7 and 28

    Systolic blood pressure measurements were measured at specific time points.

  5. Change In Oral Body Temperature

    Time frame: Days 1, 2, 3, 4, 7 and 28

    Body temperature measurements were measured at specific time points.

  6. Change In Respiratory Rate

    Time frame: Days 1, 2, 3, 4, 7 and 28

    Respiratory rate measurements were measured at specific time points.

  7. Change In Heart Rate

    Time frame: Days 1, 2, 3, 4, 7 and 28

    Heart rate measurements were measured at specific time points.

  8. Incidence of Clinically Significant 12-Lead Electrocardiogram (ECG) Findings

    Time frame: 60 days - Starting up to 28 days prior to dosing

    Number of participants per cohort with clinically significant ECG findings.

  9. Incidence of Clinically Significant Cardiac Telemetry Findings

    Time frame: 3 Days - Starting 1 day prior to dosing up to 2 days after dosing

    Number of participants per cohort with clinically significant cardiac telemetry findings.

  10. Participants Experiencing Anti-drug Antibodies (ADAs)

    Time frame: Day -3, Day -1, Day 7, and Day 28

    Incidence of Immunogenicity.

  11. Maximal Percent of Baseline Platelet Aggregation (PA(Max)) in Cohorts 4-6

    Time frame: Before dosing and at 0.5, 1, 2, 3, 6, 12, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452. IPA [maximum (max)] induced by 20 µM adenosine diphosphate (ADP) at each assessment point.

  12. Final Extent Percent of Baseline Platelet Aggregation in Cohorts 4-6

    Time frame: Before dosing and at 0.5, 1, 2, 3, 6, 12, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452. IPA [final extent] induced by 20 µM adenosine diphosphate (ADP) at each assessment point.

  13. Maximal Actual Platelet Aggregation (APA(Max)) (Cohorts 4-6)

    Time frame: Before dosing and at 0.5, 1, 2, 3, 6, 12, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose. And at 1, 2, 6, and 12 hours after the Day 2 post-MEDI2452 (PB2452) 6th ticagrelor dose (Cohorts 8 and 9 Only).

    Effectiveness Of Single Ascending Doses Of PB2452 - Inhibition of maximal platelet aggregation.

  14. Time to Maximum Platelet Aggregation (TPA(Max)) (Cohorts 4-6)

    Time frame: Before dosing and at 0.5, 1, 2, 3, 6, 12, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452 - Time to IPAmax.

  15. Maximal Percent of Baseline Platelet Aggregation (PA(Max)) (Cohorts 7-10)

    Time frame: Before dosing and at 5 min, 0.25, 0.5, 1, 2, 3, 6, 8, 10, 12, 16, 20, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose. And at 1, 2, 6, and 12 hours after the Day 2 post-MEDI2452 (PB2452) 6th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452 - IPA (max) induced by 20 µM ADP at each assessment point.

  16. Final Extent Percent of Baseline Platelet Aggregation (Cohorts 7-10)

    Time frame: Before dosing and at 5 min, 0.25, 0.5, 1, 2, 3, 6, 8, 10, 12, 16, 20, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose. And at 1, 2, 6, and 12 hours after the Day 2 post-MEDI2452 (PB2452) 6th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452 - IPA (max) induced by 20 µM ADP at each assessment point.

  17. Maximal Actual Platelet Aggregation (APA(Max)) (Cohorts 7-10)

    Time frame: Before dosing and at 5 min, 0.25, 0.5, 1, 2, 3, 6, 8, 10, 12, 16, 20, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose. And at 1, 2, 6, and 12 hours after the Day 2 post-MEDI2452 (PB2452) 6th ticagrelor dose

    Effectiveness Of Single Ascending Doses Of PB2452 - Inhibition of maximal platelet aggregation.

  18. Time to Maximum Platelet Aggregation (TPA(Max))(Cohorts 7-10)

    Time frame: Before dosing and at 5 min, 0.25, 0.5, 1, 2, 3, 6, 8, 10, 12, 16, 20, 24, and 48 hours after PB2452 infusion and 5th ticagrelor dose. And at 1, 2, 6, and 12 hours after the Day 2 post-MEDI2452 (PB2452) 6th ticagrelor dose.

    Effectiveness Of Single Ascending Doses Of PB2452 - Time to IPAmax

Sponsors and collaborators

Lead sponsor

SFJ Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Apr 10, 2018
Registry last updated
Nov 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.